Engimata
Engimata is an early stage biopharma company located in the San Francisco Bay Area, specializing in platform nano lipid particle technology for vaccine development. Their mission is to improve efficacy and stability of vaccines against infectious diseases to extend life expectancy and save lives. They develop patented lipid-based vaccine adjuvants and lipid nanoparticles (LNPs) for R&D, enabling the creation of more effective and stable vaccines across a wide temperature range (-40°C to 40°C). The company actively participates in scientific conferences, presents research on COVID-19 vaccines, and holds patents related to vaccine technology. Engimata collaborates with institutions like MIT and is recognized as an economic driver in Pleasanton, CA.
Industries
Nr. of Employees
small (1-50)
Engimata
3197 Independence Drive, Livermore, CA 94551
Patents
Immunogenic composition forming a vaccine, and a method for its manufacture
US-11559577-B2
View DetailsImmunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
US-11278617-B2
View Details
Immunogenic composition forming a vaccine, and a method for its manufacture
US-11559577-B2
View DetailsImmunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
US-11278617-B2
View DetailsProducts
Lipid nanoparticle-based vaccine adjuvant platform
A lipid-based particulate adjuvant and delivery platform formulated with natural lipids and approved excipients to enhance immune response, improve antigen stability, and enable thermostable vaccine formats.
Lipid nanoparticle-based vaccine adjuvant platform
A lipid-based particulate adjuvant and delivery platform formulated with natural lipids and approved excipients to enhance immune response, improve antigen stability, and enable thermostable vaccine formats.
Services
Supply of liposome or lipid nanoparticle formulations and adjuvant delivery systems for use in vaccine research and development; formulations can be customized for different antigens.
Supply of liposome or lipid nanoparticle formulations and adjuvant delivery systems for use in vaccine research and development; formulations can be customized for different antigens.
Expertise Areas
- Vaccine adjuvant development
- Lipid nanoparticle and liposome formulation
- Thermostable vaccine formulation
- Lyophilization / freeze-drying for biologics
Key Technologies
- Liposomal nanoparticles
- Lipid nanoparticles (LNP)
- Lyophilization / freeze-drying
- Thermal analysis
News & Updates
Presentations @2024 AAPS PharmSci 360
Poster presentations on liposome aggregation behavior and protein antigen characterization, scheduled for Oct 20-23, 2024 in Salt Lake City.
AAPS National Biotechnology Conference 2024
Engimata presented two posters on liposome behavior and vaccine stability in San Francisco, May 13-16, 2024.
AAPS PharmSci 360 Presentation
CSO Dr. Rajiv Nayar presented a poster on COVID-19 vaccine research in Orlando, FL, Oct 25, 2024.
A Versatile Room Temperature Stable Lipid Nanoparticle COVID-19 Protein-Based Vaccine
Presented at the AAPS PharmSci 360, Orlando, FL, Oct 20-22, 2023.
International Society for Vaccines (ISV) Congress
Research on next-generation COVID-19 vaccine presented virtually, Oct 22-24, 2023.
World Vaccine Congress
Engimata exhibited at the startup pavilion, Oct 26, 2023.
Presentations @2024 AAPS PharmSci 360
Poster presentations on liposome aggregation behavior and protein antigen characterization, scheduled for Oct 20-23, 2024 in Salt Lake City.
AAPS National Biotechnology Conference 2024
Engimata presented two posters on liposome behavior and vaccine stability in San Francisco, May 13-16, 2024.
AAPS PharmSci 360 Presentation
CSO Dr. Rajiv Nayar presented a poster on COVID-19 vaccine research in Orlando, FL, Oct 25, 2024.
A Versatile Room Temperature Stable Lipid Nanoparticle COVID-19 Protein-Based Vaccine
Presented at the AAPS PharmSci 360, Orlando, FL, Oct 20-22, 2023.
International Society for Vaccines (ISV) Congress
Research on next-generation COVID-19 vaccine presented virtually, Oct 22-24, 2023.
World Vaccine Congress
Engimata exhibited at the startup pavilion, Oct 26, 2023.